Ascletis reports its oral GLP-1 pill met the main goal of a Phase II diabetes study, while its global obesity trials keep moving forward.
Recap by typeshit. Full story at AllSci.
A Facebook share says Danish teams found certain bacterial strains may change how the gut tells the brain it is full. The work so far is in animal models only.
Bikman calls the results remarkable, but he argues that bigger drops make it more important to know how much of the lost weight is fat and how much is muscle.
Bikman points out that weight usually returns once the drug is stopped, which makes the question of lifelong use a real one.
Avi Roy flags a preprint that pooled 10,052 people from five semaglutide trials and used a blood test to estimate heart age. It has not yet been peer reviewed.
The Independent Medical Alliance doctor weighs in on what is still unknown about the long-term safety of GLP-1 drugs used by millions of Americans.
Millions of Americans are losing weight on GLP-1 shots, and The National Desk looks at what remains unanswered about them.
Loading…